Category: Oncology

Clinical Trials News Oncology

Breakthrough in Bladder Cancer Treatment: PADCEV and KEYTRUDA Combination Significantly Improves Survival

pfizer news

A landmark clinical trial reveals a powerful new weapon against aggressive bladder cancer. The combination of PADCEV™ and KEYTRUDA®, administered before and after surgery, has been shown to significantly improve survival rates for patients with muscle-invasive bladder cancer who are ineligible for cisplatin chemotherapy. These groundbreaking results could establish a new standard of care, offering profound hope for a patient population with previously limited options.

Clinical Trials News Oncology

Lilly’s Verzenio® Shows Significant Survival Benefit in High-Risk Early Breast Cancer

Eli Lilly and Company

Eli Lilly and Company announced major findings from the seven-year monarchE trial. Their CDK4/6 inhibitor, Verzenio® (abemaciclib), is the first in its class to demonstrate a statistically significant overall survival benefit for patients with HR+, HER2-, high-risk early breast cancer when added to endocrine therapy.

Oncology News

ESMO 2025 Preview: Roche, Lilly, AbbVie, and Gilead to Present Latest Oncology Data

ESMO_2025

Leading pharmaceutical companies including Roche, Eli Lilly, AbbVie, and Gilead/Kite are set to present significant new data from their oncology pipelines at the ESMO Congress 2025 in Berlin (Oct 17-21). Presentations will highlight advancements in targeted therapies, ADCs, and cell therapy for multiple cancer types, focusing on key drugs like Tecentriq, Verzenio, and Trodelvy.

Research Cancer News

‘Proteotoxic Shock’: Ohio State Researchers Uncover Hidden Mechanism Behind Immunotherapy Failure

Recent Cancer Research Shows Treatment Efficacy With Lupus-Related Antibody

A landmark study by Ohio State scientists reveals the underlying mechanism of cancer immunotherapy failure: a fatal “proteotoxic shock” or protein quality control collapse (TexPSR) in T-cells. This newly identified stress pathway overwhelms immune cells with misfolded proteins, disabling their tumor-fighting function. Crucially, blocking the TexPSR pathway in preclinical models restored T-cell function and made immunotherapy markedly more effective, offering an entirely new target for cancer treatment development.

Regulatory Approval News Oncology

FDA Approves Groundbreaking Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Roche

In a major breakthrough for oncology, the U.S. FDA has approved a new combination therapy from Roche for a highly aggressive form of lung cancer. The treatment, which combines Tecentriq® (atezolizumab) and lurbinectedin (Zepzelca®), is the first of its kind for the maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC). Clinical trial results show the regimen significantly reduces the risk of disease progression and death, offering new hope and a pivotal shift in how this challenging disease is managed post-chemotherapy.

Clinical Trials Biologics News Oncology

Amgen’s Repatha® (evolocumab) Succeeds in Landmark Phase 3 Trial, Showing Significant Reduction in Cardiovascular Events

amgen

Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial for Repatha® (evolocumab) met its primary endpoints, demonstrating a significant reduction in the risk of major adverse cardiovascular events (MACE) in high-risk individuals without a prior history of heart attack or stroke. The study, which enrolled over 12,000 patients, positions Repatha as the first and only PCSK9 inhibitor to show such a benefit in this primary prevention setting, offering a new hope for patients at high risk for cardiovascular disease.

Oncology News Regulatory Approval

FDA Approves Lilly’s Inluriyo (imlunestrant) for Advanced ER+, HER2- Breast Cancer with ESR1 Mutation

Eli Lilly and Company

The U.S. Food and Drug Administration (FDA) has officially approved Eli Lilly and Company’s Inluriyo (imlunestrant), a new oral therapy for adult patients with advanced or metastatic estrogen receptor-positive (ER+), HER2-negative breast cancer that has an ESR1 mutation. The approval is based on the pivotal Phase 3 EMBER-3 trial, which demonstrated that Inluriyo significantly reduced the risk of disease progression or death by 38% in this patient population, offering a new and convenient treatment option for a challenging form of breast cancer.

Clinical Trials Healthcare & Pharmaceuticals News Oncology

Roche’s Giredestrant Combination Shows Significant Benefit in Advanced ER-Positive Breast Cancer

Roche

Roche’s Phase III evERA study for the investigational drug giredestrant has delivered positive results, showing a significant improvement in progression-free survival for patients with advanced ER-positive breast cancer. The all-oral combination therapy, which was well-tolerated, offers a new, promising treatment option for individuals whose disease has progressed after previous treatments.